Murugesan Vanangamudi

Author

Central Drug Research Institute ORCID

Also Known As

Bibhash Chandra Mohanta, Murugesan Vanangamudi, V. Murugesan, Vanangamudi Murugesan, Vanangamudi, Murugesan

Publications

642

Citations

H-Index

Concepts

All Affiliations

Central Drug Research Institute National AIDS Research Institute Swami Vivekanand College of Pharmacy Mohanlal Sukhadia University University of Bonn

About

Murugesan Vanangamudi is an author at Central Drug Research Institute specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	405
2	Natural Sciences	4	4	107
3	Biomolecular Engineering	3	3	236
4	Biochemistry	2	2	52
5	Engineering	1	1	30

Murugesan Vanangamudi

Publications

461

Citations

H-Index

Page 1

	Year	Citations
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic Vigneshwaran Namasivayam, Murugesan Vanangamudi, Victor G. Kramer, Journal of Medicinal Chemistry ImmunologyPharmacotherapyAntiviral DrugHuman Immunodeficiency VirusDrug Resistance	2018	177
Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains Rahul Suryawanshi, Sushama Jadhav, Nandini Makwana, Bioorganic Chemistry MedicineAntiviral Drug DevelopmentResistance Mutation (Virology)Pharmacotherapy4-Thiazolidinone Derivatives	2017	45
Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors Murugesan Vanangamudi, Vinay Shankar Tiwari, Reshu Saxena, Bioorganic & Medicinal Chemistry Medicinal ChemistryBiochemistryMedicineNatural SciencesRational Drug Design	2011	40
CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents Murugesan Vanangamudi, Yenamandra S. Prabhakar, S. B. Katti Journal of Molecular Graphics and Modelling Medicinal ChemistryMedicineImmunologyComsia StudiesPharmacotherapy	2008	38
Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors Murugesan Vanangamudi, Nandini Makwana, Rahul Suryawanshi, Bioorganic & Medicinal Chemistry Combinatorial ChemistryMedicinal ChemistryRational DesignMedicineAntiviral Drug Development	2014	38
Synthesis of sulpha drug based hydroxytriazene derivatives: Anti-diabetic, antioxidant, anti-inflammatory activity and their molecular docking studies Poonam Sharma, Varsha Dayma, Aparna Dwivedi, Bioorganic Chemistry Molecular Docking StudiesMedicinal ChemistrySulpha DrugNatural SciencesMedicine	2020	34
Is Feature Selection Essential for ANN Modeling? Mohammad Goodarzi, Shreekant Deshpande, Murugesan Vanangamudi, QSAR & Combinatorial Science Artificial IntelligenceSearch OptimizationEngineeringMachine LearningFeature Selection	2009	30
Synthesis, antidiabetic, antioxidant and anti-inflammatory activities of novel hydroxytriazenes based on sulpha drugs Varsha Dayma, Jaishri Chopra, Poonam Sharma, Heliyon	2020	26
Integrative approaches in <scp>HIV</scp>‐1 non‐nucleoside reverse transcriptase inhibitor design Vasanthanathan Poongavanam, Vigneshwaran Namasivayam, Murugesan Vanangamudi, Wiley Interdisciplinary Reviews Computational Molecular Science Drug TargetMolecular BiologyIntegrative ApproachesMolecular DesignHiv ‐1 Rt	2017	21
CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements Murugesan Vanangamudi, Nidhi Sethi, Yenamandra S. Prabhakar, Molecular Diversity Medicinal ChemistryBiochemistryMedicineActive Site RequirementsNatural Sciences	2010	12

Page 1